FR2820636B1 - Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2 - Google Patents

Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2

Info

Publication number
FR2820636B1
FR2820636B1 FR0101772A FR0101772A FR2820636B1 FR 2820636 B1 FR2820636 B1 FR 2820636B1 FR 0101772 A FR0101772 A FR 0101772A FR 0101772 A FR0101772 A FR 0101772A FR 2820636 B1 FR2820636 B1 FR 2820636B1
Authority
FR
France
Prior art keywords
indometacin
oxygenase
pathologies
cyclo
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0101772A
Other languages
English (en)
Other versions
FR2820636A1 (fr
Inventor
Abderrahim Bennis
Jean Jacques Serrano
Farid Bennis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAPROPHAN LABORATOIRES DE PROD
Original Assignee
LAPROPHAN LABORATOIRES DE PROD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LAPROPHAN LABORATOIRES DE PROD filed Critical LAPROPHAN LABORATOIRES DE PROD
Priority to FR0101772A priority Critical patent/FR2820636B1/fr
Priority to PCT/FR2002/000490 priority patent/WO2002064134A2/fr
Publication of FR2820636A1 publication Critical patent/FR2820636A1/fr
Application granted granted Critical
Publication of FR2820636B1 publication Critical patent/FR2820636B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0101772A 2001-02-09 2001-02-09 Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2 Expired - Lifetime FR2820636B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0101772A FR2820636B1 (fr) 2001-02-09 2001-02-09 Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2
PCT/FR2002/000490 WO2002064134A2 (fr) 2001-02-09 2002-02-08 Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0101772A FR2820636B1 (fr) 2001-02-09 2001-02-09 Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2

Publications (2)

Publication Number Publication Date
FR2820636A1 FR2820636A1 (fr) 2002-08-16
FR2820636B1 true FR2820636B1 (fr) 2007-10-05

Family

ID=8859826

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0101772A Expired - Lifetime FR2820636B1 (fr) 2001-02-09 2001-02-09 Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2

Country Status (2)

Country Link
FR (1) FR2820636B1 (fr)
WO (1) WO2002064134A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790706B2 (en) 2002-06-14 2010-09-07 The University Of Edinburgh Treatment of inflammation with 5α reduced metabolites
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
EP1396547A1 (fr) * 2002-09-05 2004-03-10 Universitair Medisch Centrum Utrecht Métabolites d'acide arachidonique et modulation de la mitose et de l'apoptose de cellules

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758819B1 (fr) * 1997-01-29 2000-01-21 Laprophan Laboratoires Pharma Indometacine calcique et sa preparation
US6008260A (en) * 1998-01-09 1999-12-28 Pharmascience Cancer chemopreventative composition and method
US6046231A (en) * 1998-05-15 2000-04-04 The Board Of Trustees Of The University Of Illinois Use of 4'-bromoflavone in a cancer chemopreventative composition and method
US6649645B1 (en) * 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia

Also Published As

Publication number Publication date
FR2820636A1 (fr) 2002-08-16
WO2002064134A3 (fr) 2003-10-16
WO2002064134A8 (fr) 2004-04-29
WO2002064134A2 (fr) 2002-08-22

Similar Documents

Publication Publication Date Title
MA26264A1 (fr) Kits pour la purification d'eau
FR2804288B1 (fr) Ensemble d'adaptation pour casque
MA27126A1 (fr) 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
DE60044625D1 (de) Système d'assistance de conduire pour vehicules
FR2798590B1 (fr) Utilisation de l'alverine pour diminuer les rides
DE69731674D1 (de) Silencieux d'aspiration pour compresseur
MA26028A1 (fr) Dessalement de l'eau
FR2769494B1 (fr) Piece femorale pour prothese de genou
EP1177025A4 (fr) Pack d'epuration d'eau ameliore
FR2827170B1 (fr) Utilisation de peptides pour augmenter l'adhesion cellulaire
FR2742980B1 (fr) Compositions pour electrodes biomedicales a usage unique
MA26950A1 (fr) Nouveaux retinoides pour le traitement de l'emphyseme
FR2821545B1 (fr) Ensemble prothetique pour l'articulation de l'epaule
FR2762376B3 (fr) Tuyau flexible ameliore pour adduction d'eau
FR2813370B1 (fr) Joints d'etancheite pour la traversee de parois
FR2822071B1 (fr) Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques
EP1141240A4 (fr) Utilisation de l'accouplement de cd40 pour modifier l'usage du recepteur des lymphocytes t
FR2820636B1 (fr) Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2
FR2765482B1 (fr) Utilisation de l'acide y-linolenique pour prevenir le stress oxydatif
FR2825612B1 (fr) Instrument pour dilater l'ouverture d'une trachee
FR2839453B1 (fr) Utilisation de novirhabdovirus modifies pour l'obtention de vaccins
FR2830168B1 (fr) Bac pour vegetaux avec reserve d'eau etanche
BR9911006A (pt) Purificação de carboxaldeìdo
EP1066061A4 (fr) Utilisation du facteur de dispersion pour favoriser l'angiogenese
FR2815392B3 (fr) Tube flexible pour l'irrigation

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 20